Literature DB >> 15916013

Bacillus clausii exerts immuno-modulatory activity in allergic subjects: a pilot study.

Giorgio Ciprandi1, Andrea Vizzaccaro, Ignazio Cirillo, Maria Angela Tosca.   

Abstract

UNLABELLED: Bacillus clausii has been demonstrated to exert some immunomodulatory activities and to be safe. Allergic subjetcs show Th2 polarization and defect of T regulatory cells. Aim of the study was to investigate whether Bacillus clausii administration in allergic subjects might modulate cytokine pattern. Ten subjects (mean age 22.3 years) suffering from allergic rhinitis were enrolled. Bacillus clausii spores (Enterogermina: 2 billions spores/vial) were administered at the dosage schedule of 3 vials a day for 4 weeks. Nasal lavage was performed in all subjects before and after the treatment. A panel of cytokines, including IL4, IL10, IFNgamma, and TGFbeta, was measured by immunoassay in the fluid recovered from nasal lavage, before and after the treatment.
RESULTS: Bacillus clausii treatment showed a significant decrease of IL4 levels (p=0.004) and a significant increase of IFNgamma (p=0.038), TGFbeta (p=0.039), and IL10 (p=0.009) levels. In conclusion, this study shows that the Bacillus clausii may exert immuno-modulating activity by affecting cytokine pattern in allergic subjects and confirms previous study conducted in allergic children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15916013

Source DB:  PubMed          Journal:  Eur Ann Allergy Clin Immunol        ISSN: 1764-1489


  8 in total

1.  Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study).

Authors:  D J Costa; P Marteau; M Amouyal; L K Poulsen; E Hamelmann; M Cazaubiel; B Housez; S Leuillet; M Stavnsbjerg; P Molimard; S Courau; J Bousquet
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

2.  Inhibition of Lipopolysaccharide-Induced Interleukin 8 in Human Adenocarcinoma Cell Line HT-29 by Spore Probiotics: B. coagulans and B. subtilis (natto).

Authors:  Masoumeh Azimirad; Masoud Alebouyeh; Tahereh Naji
Journal:  Probiotics Antimicrob Proteins       Date:  2017-03       Impact factor: 4.609

Review 3.  Current Progress and Future Perspectives on the Use of Bacillus clausii.

Authors:  Emilia Ghelardi; Ana Teresa Abreu Y Abreu; Christian Boggio Marzet; Guillermo Álvarez Calatayud; Marcos Perez; Ana Paula Moschione Castro
Journal:  Microorganisms       Date:  2022-06-17

4.  Probiotics and small bowel mucosa: Molecular aspects of their interactions.

Authors:  N Saulnier; M A Zocco; S Di Caro; G Gasbarrini; A Gasbarrini
Journal:  Genes Nutr       Date:  2006-06       Impact factor: 5.523

5.  Secreted Compounds of the Probiotic Bacillus clausii Strain O/C Inhibit the Cytotoxic Effects Induced by Clostridium difficile and Bacillus cereus Toxins.

Authors:  Gabrielle Ripert; Silvia M Racedo; Anne-Marie Elie; Claudine Jacquot; Philippe Bressollier; Maria C Urdaci
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 6.  Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review.

Authors:  Lynne V McFarland
Journal:  BMJ Open       Date:  2014-08-25       Impact factor: 2.692

7.  Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study.

Authors:  Gian Luigi Marseglia; Mariangela Tosca; Ignazio Cirillo; Amelia Licari; Maddalena Leone; Alessia Marseglia; Anna Maria Castellazzi; Giorgio Ciprandi
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

Review 8.  The role of probiotics and prebiotics in inducing gut immunity.

Authors:  Angélica T Vieira; Mauro M Teixeira; Flaviano S Martins
Journal:  Front Immunol       Date:  2013-12-12       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.